Skip to main content
    T

    Tscan Therapeutics Inc (TCRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.15
    +0.01 (+4.07%)

    Market Cap: $10.89M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Tscan Therapeutics Inc (TCRX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Tscan Therapeutics (TCRX) has a market cap of $10.89M. It kept -2219.19% of revenue as net income over the last 12 months. It holds $40.07M more cash than debt, 368.07% of its market cap.

    Total Valuation

    Market Cap$10.89M
    Latest price (Nov 17, 2026)$0.15

    Key Dates

    The next earnings report is expected on Mar 2, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 2, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.06% in the quarter ended Sep 30, 2026 and grew 4.66% a year over 2 years.

    Shares Outstanding130.03M
    Shares Change (YoY)+0.15%
    Shares Change (QoQ)+0.06%
    Share Count Growth (2Y CAGR)+4.66%

    Valuation Ratios

    Sales and book value multiples are 3.8x and 0.5x. Its year-end P/S ranged from 1.9x to 121.4x from 2021 to 2025.

    P/S Ratio3.8x
    Forward P/S3.4x
    P/B Ratio0.5x

    Valuation history and multiples

    Price Statistics

    The stock is down 86.27% over 52 weeks and trades 40.00% below its 50-day average.

    Beta (1Y)1.83
    52-Week Change-86.27%
    1-Month Change-28.16%
    3-Month Change-79.87%
    6-Month Change-84.32%
    5-Year Change-98.01%
    Total Return (1Y)-86.27%
    Total Return (3Y CAGR)-69.54%
    Total Return (5Y CAGR)-55.62%
    Max Drawdown (1Y)-89.85%
    Max Drawdown (3Y)-98.47%
    Sharpe Ratio (1Y)-1.89
    Correlation with SPY (1Y)0.25
    50-Day Average$0.25
    200-Day Average$0.80
    52-Week Range$0.14 to $1.47
    RSI (14 Days)30.7
    Average Volume (20 Days)450.42K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.03x current liabilities, and total debt is 0.87x shareholder equity.

    Current Ratio2.03x
    Quick Ratio2.03x
    Debt / Equity0.87x
    Interest Coverage-40.69x

    Returns and Efficiency

    Return on invested capital is -129.74% over the last 12 months, against a 5-year average of -47.41%.

    Return on Equity (ROE)-302.77%
    Return on Assets (ROA)-81.39%
    Return on Invested Capital (ROIC)-129.74%
    ROE (5Y Average)-62.86%
    ROA (5Y Average)-36.59%
    ROIC (5Y Average)-47.41%
    Asset Turnover0.03x

    Scores

    TCRX has an Altman Z-Score of -8.15, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-8.15
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $5.19M over the last 12 months is down 38.43% from the 12 months before.

    Revenue$5.19M
    Revenue Growth (YoY)-38.43%
    Gross Profit$5.19M
    Operating Income-$116.52M
    Pretax Income-$115.14M
    Net Income-$115.09M
    EBITDA-$113.78M
    Reported EPS (TTM)-$0.88

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 26.88% of the $141.40M in total assets.

    Cash and Equivalents$73.04M
    Total Debt$32.97M
    Net Cash$40.07M
    Net Cash Per Share$0.31
    Working Capital$38.97M
    Shareholder Equity$38.01M
    Book Value Per Share$0.29
    Total Assets$141.40M
    Total Liabilities$103.39M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $775.00K of capital spending, operating cash flow left -$111.67M of free cash flow.

    Operating Cash Flow-$110.89M
    Capital Expenditures$775.00K
    Free Cash Flow-$111.67M
    FCF Per Share-$1.76
    Depreciation and Amortization$2.79M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -2246.84%.

    Gross Margin100.00%
    Operating Margin-2246.84%
    Pretax Margin-2220.23%
    Net Margin-2219.19%
    EBITDA Margin-2194.02%
    FCF Margin-2153.26%

    Growth

    Revenue fell 8.63% a year over 3 years.

    Revenue Growth (3Y CAGR)-8.63%
    Revenue Growth (5Y CAGR)+56.92%
    Book Value Per Share Growth (2Y CAGR)-22.80%
    Tangible Book Per Share Growth (2Y CAGR)-22.80%

    Revenue and profit by year

    Dividends and Yields

    TCRX does not pay a dividend. Its free cash flow yield is -568.75%.

    FCF Yield-568.75%
    Buyback Yield-0.88%
    Shareholder Yield-0.88%

    Peer Position

    Against 4 similar companies, TCRX has the 4th highest P/S.

    P/S Ratio3.8x vs 15.6x median
    ROIC-129.74% vs -281.41% median
    Revenue Growth (Trailing 4 Quarters, YoY)-38.43% vs -41.95% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -59.82% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-59.82%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TCRX

    What is TCRX's market cap?

    Tscan Therapeutics has a market cap of $10.89M.

    How many shares of TCRX are outstanding?

    Tscan Therapeutics has 130.03M shares outstanding. The count is up 0.15% from a year earlier.

    Does TCRX pay a dividend?

    No. Tscan Therapeutics does not pay a dividend.

    How much debt does TCRX have?

    Tscan Therapeutics has $32.97M of total debt and $73.04M of cash and equivalents, a net cash position of $40.07M.